In consideration of over-expression of FGF-21 in vivo has been shown to ameliorate fatty liver [105], pharmacological inhibition of endogenous miR-149 might be a new therapeutic strategy for NAFLD. Here, FGF21 is linked to metabolic dysfunction-associated steatotic liver disease.